Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution-Reference-Cited by-同舟云学术

Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution

Published:2009-12-09 Issue:10 Volume:1 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Sikorski Robert¹,Yao Bin¹

Affiliation:

1. Amgen, Thousand Oaks, CA 91320, USA.

Abstract

Predictive biomarkers can be integrated into phase III clinical trials by several approaches, including one that anticipates that a new biomarker will emerge during the course of the trial.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference11 articles.

1. The Use of Genomics in Clinical Trial Design

2. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset

3. Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

4. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

5. Cetuximab for the Treatment of Colorectal Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis of Cancer;Molecular Targets and Cancer Therapeutics (Part 2);2023-04-19

2. Clinical Application of Molecular Features in Therapeutic Selection and Drug Development;Statistical Methods in Biomarker and Early Clinical Development;2019

3. Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial with Time-to-Event Data: Comparing Group Sequential and Various Adaptive Enrichment Designs;Statistics in Biosciences;2017-06-12

4. The Importance of Biopsy in the Era of Molecular Medicine;The Cancer Journal;2016-11

5. Biomarker Applications in the Pharmaceutical Industry;The Path from Biomarker Discovery to Regulatory Qualification;2013